Everolimus With and Without Temozolomide in Adult Low Grade Glioma
PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma
Sponsor: Novartis
Terminated
Sponsor decision
Other terminated trials from Novartis
This PHASE2 trial investigates Low Grade Glioma and Mixed Oligoastrocytomas and is currently terminated or withdrawn. Novartis leads this study, which shows 12 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Feb 2023 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .